Available online 6 April 2023, 101464

Adoptive cellular immunotherapy, mainly hematopoietic stem cell transplant and CAR-T cell therapy have revolutionized treatment of patients with acute leukemia. Indications and inclusion criteria for these treatments have expanded in recent years. While these therapies are associated with significant improvements in disease response and overall survival, patients may experience adverse events from associated chemotherapy conditioning, engraftment, cytokine storm, supportive medications, and post-transplant maintenance targeted therapies. Supportive oncodermatology is a growing specialty to manage cutaneous toxicities resulting from the anti-cancer therapies. In this review, we summarize diagnosis and management of the common cutaneous adverse events including drug eruptions, graft-versus-host disease, neoplastic and paraneoplastic complications in patients undergoing cellular therapies.

Toxic erythema of chemotherapy (TEC) encompasses a wide array of non-allergic cutaneous eruptions to chemotherapeutic drugs. Historically, these eruptions went by many, often redundant, names, based primarily on clinical or histologic features. Some examples include hand foot syndrome (HFS), palmar plantar erythema/erythrodysesthesia, intertriginous eruptions associated with chemotherapy, and intertrigo dermatitis. TEC is a new term that broadly encompasses these, such that confusion among

Alemtuzumab is a monoclonal antibody that binds to CD52, an antigen that can be found on both normal and malignant mature lymphocytes. It is currently FDA approved for the treatment of chronic lymphocytic leukemia and has been used in some protocols as part of the preparative regimen for alloHCT. DAEs occur frequently among patients taking this medication – in clinical trials, patients experienced rash (52%), urticaria (16%), pruritus (14%), flushing (10%), dermatitis (8%), erythema (5%), and

Patients with acute leukemia have an increased risk for infection. The malignancy itself can lead to the production of defective lymphocytes with impaired cell-mediated immunity, and prolonged treatment with chemotherapy can cause severe neutropenia, ultimately increasing the risk of fungal, bacterial, and viral infections [41]. Oftentimes, antimicrobials are given prophylactically to these patients to prevent the development of severe infections. As a result, patients with acute leukemia are

Becoming familiar with acute cutaneous complications of cellular therapies in patients with acute leukemia.

Early diagnosis of the skin toxicities to intervene at earlier stages.

Preventive measures regarding increased risk of future cutaneous malignancies in patients.

Review Article; Regarding the broad nature of the topic, the authors tried to provide a concise and at the same time comprehensive coverage for the readers regarding the most important and widely seen cutaneous complications of cellular therapies.

Research funding from Incyte Corporation and Amryt Pharma; Consults for ADC Therapeutics, Blueprint Medicines, Alira Health, Protagonist Therapeutics, OnQuality, and Janssen; Royalties from UpToDateThis study was supported by the NIH/NCI Cancer Center Support Grant P30-CA008748.

Dr Babakoohi, Stepahnie Gu and Dr Ehsan have no disclosures.

© 2023 Published by Elsevier Ltd.